

# CITATION REPORT

List of articles citing

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

DOI: 10.1080/14767050701830480

Journal of Maternal-Fetal and Neonatal Medicine, 2008  
, 21, 9-23.

Source: <https://exaly.com/paper-pdf/44361392/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
542	Advances in the understanding of eclampsia. <b>2008</b> , 10, 305-12		42
541	Circulating soluble endoglin and placental abruption. <b>2008</b> , 28, 852-8		35
540	Twin-to-twin transfusion syndrome: an antiangiogenic state?. <b>2008</b> , 198, 382.e1-8		45
539	Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. <b>2008</b> , 29, 555-63		66
538	Severe preeclampsia is characterized by increased placental expression of galectin-1. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2008</b> , 21, 429-42	2	54
537	The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2008</b> , 21, 279-87	2	221
536	The role of an 'anti-angiogenic state' in complications of pregnancy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2008</b> , 21, 3-7	2	4
535	Physiological and pathophysiological roles of placental aminopeptidase in maternal sera: possible relation to preeclampsia and preterm delivery. <b>2009</b> , 3, 479-91		3
534	Maternal serum adiponectin multimers in preeclampsia. <b>2009</b> , 37, 349-63		54
533	Placental vascular pathology findings and pathways to preterm delivery. <b>2009</b> , 170, 148-58		84
532	Maternal serum adiponectin multimers in patients with a small-for-gestational-age newborn. <b>2009</b> , 37, 623-35		23
531	Hypotension in obstetric spinal anaesthesia: a lesson from pre-eclampsia. <b>2009</b> , 102, 291-4		72
530	Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. <b>2009</b> , 22, 891-5		42
529	Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. <b>2009</b> , 124, e450-8		190
528	Circulating angiogenic factors in gestational proteinuria without hypertension. <b>2009</b> , 200, 392.e1-10		31
527	Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia?. <b>2009</b> , 201, 595.e1-5		42
526	Facteurs anti-angiogéniques et prééclampsie au cours de la grossesse diabétique de type 1. <b>2009</b> , 1, 9-10		

525	Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. <b>2009</b> , 52, 160-8		44
524	First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. <b>2009</b> , 29, 781-9		61
523	Pulse wave analysis: a preliminary study of a novel technique for the prediction of pre-eclampsia. <b>2009</b> , 116, 268-76; discussion 276-7		66
522	First trimester urinary placental growth factor and development of pre-eclampsia. <b>2009</b> , 116, 643-7		23
521	A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. <b>2009</b> , 116, 1473-80		17
520	Maternal plasma and amniotic fluid angiogenic factors and their receptors in monochorionic twin pregnancies complicated by twin-to-twin transfusion syndrome. <b>2010</b> , 35, 695-701		16
519	Maternal periodontal disease and soluble fms-like tyrosine kinase-1 expression. <b>2009</b> , 80, 1506-10		5
518	Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. <b>2009</b> , 3, 65-73		49
517	Potential markers of preeclampsia--a review. <b>2009</b> , 7, 70		184
516	Dysregulation of maternal serum adiponectin in preterm labor. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 887-904	2	27
515	A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 1122-39	2	59
514	Maternal plasma visfatin in preterm labor. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 693-704	2	28
513	A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 1021-38	2	209
512	The great obstetrical syndromes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2009</b> , 22, 633-5	2	96
511	Current world literature. Ageing: biology and nutrition. <b>2009</b> , 12, 95-100		
510	Recurring complications in second pregnancy. <b>2009</b> , 113, 1217-1224		76
509	The perinatal implications of angiogenic factors. <b>2009</b> , 21, 111-6		34
508	Angiogenic proteins and adipocytokines as markers for prediction of preeclampsia. <b>2010</b> , 5, 717-725		4

507	Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. <b>2010</b> , 35, 155-62	33
506	Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies. <b>2010</b> , 35, 280-5	29
505	Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. <b>2010</b> , 35, 680-7	58
504	Beyond the threshold: an etiological bridge between hypoxia and immunity in preeclampsia. <b>2010</b> , 85, 112-6	29
503	Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. <b>2010</b> , 202, 40.e1-7	96
502	An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. <b>2010</b> , 202, 161.e1-161.e11	277
501	Defining normal and abnormal fetal growth: promises and challenges. <b>2010</b> , 202, 522-8	184
500	Angiogenic imbalances: the obstetric perspective. <b>2010</b> , 203, 17.e1-8	34
499	Early-pregnancy soluble Fas levels in idiopathic small-for-gestational-age pregnancies. <b>2010</b> , 202, 299.e1-7	5
498	Allelic variations in angiogenic pathway genes are associated with preeclampsia. <b>2010</b> , 202, 445.e1-11	38
497	A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. <b>2010</b> , 202, 550.e1-10	24
496	Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. <b>2010</b> , 203, 383.e1-8	118
495	Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. <b>2010</b> , 221, 363-78	145
494	Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. <b>2010</b> , 30, 191-7	40
493	The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. <b>2010</b> , 117, 456-62	59
492	First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. <b>2010</b> , 117, 1384-9	76
491	Do pregnancies with pre-eclampsia have smaller placentas? A population study of 317 688 pregnancies with and without growth restriction in the offspring. <b>2010</b> , 117, 1521-6	22
490	The epidemiology of preeclampsia with focus on family data. 195-206	

489	Angiogenic factors and preeclampsia. 229-242		0
488	Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PLGF) in preeclampsia among high risk pregnancies. <b>2010</b> , 5, e13263		107
487	New-onset maternal gestational hypertension and risk of retinopathy of prematurity. <b>2010</b> , 51, 4983-8		20
486	Biomarkers in Obstetric Medicine. <b>2010</b> , 323-353		
485	Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry?. <b>2010</b> , 17, 861-70		17
484	Uterine artery Doppler in first-trimester pregnancy screening. <b>2010</b> , 53, 879-87		21
483	Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses. <b>2010</b> , 38, 495-502		58
482	Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. <b>2010</b> , 38, 503-13		59
481	Retinol binding protein 4--a novel association with early-onset preeclampsia. <b>2010</b> , 38, 129-39		44
480	Markers of preeclampsia and the relationship to cardiovascular disease: review of the twenty-first century literature. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 751-69	2	11
479	Levels of antiangiogenic factors in preeclamptic pregnancies. <b>2010</b> , 28, 293-8		6
478	Sildenafil for the treatment of preeclampsia. <i>Hypertension in Pregnancy</i> , <b>2010</b> , 29, 248-50; author reply 251-2	2	12
477	Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 476-87	2	36
476	Pathogenesis of preeclampsia. <b>2010</b> , 5, 173-92		466
475	Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 1119-28	2	27
474	Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. <b>2010</b> , 122, 478-87		259
473	Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. <b>2010</b> , 177, 2950-62		98
472	Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay. <b>2010</b> , 177, 2387-98		59

471	The use of angiogenic factors in discriminating preeclampsia: are they ready for prime time?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 1294-300	2	10
470	Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 820-7	2	19
469	An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 1384-299	2	48
468	Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 857-68	2	29
467	Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 167-78	2	21
466	Fetal death: a condition with a dissociation in the concentrations of soluble vascular endothelial growth factor receptor-2 between the maternal and fetal compartments. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 960-72	2	9
465	Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 828-41	2	19
464	Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 794-805	2	17
463	Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2010</b> , 23, 646-57	2	43
462	Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2011</b> , 24, 1187-207	2	100
461	Angiogenic factors and preeclampsia. <b>2011</b> , 31, 33-46		286
460	Identification of the primary outcomes that result from deficient spiral arterial modification in pregnant mice. <b>2011</b> , 1, 87-94		32
459	Preeclampsia and the Anti-Angiogenic State. <b>2011</b> , 1, 17-21		60
458	Circulating predictive biomarkers in preeclampsia. <b>2011</b> , 1, 28-42		21
457	sFlt-1 and IP-10 in women with early-onset preeclampsia. <b>2011</b> , 1, 129-31		4
456	Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. <b>2011</b> , 29, 148-54		133
455	Enhanced angiogenic capacity of human umbilical vein endothelial cells from women with preeclampsia. <b>2011</b> , 18, 374-82		10
454	Hypertension and kidney disease in pregnancy: introduction. <b>2011</b> , 31, 1-3		

453	High early uterine vascular resistance values increase the risk of adverse pregnancy outcome independently from placental VEGF and VEGFR1 reactivities. <b>2011</b> , 156, 165-70	2
452	Maternal angiogenic profile in pregnancies that remain normotensive. <b>2011</b> , 158, 189-93	20
451	Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. <b>2011</b> , 6, e16681	46
450	Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. <b>2011</b> , 66, 225-39	133
449	Is inflammation the cause of pre-eclampsia?. <b>2011</b> , 39, 1619-27	81
448	A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy. <b>2011</b> , 90, 1244-51	26
447	Uterine Regulatory T cells, IL-10 and hypertension. <b>2011</b> , 66 Suppl 1, 88-92	34
446	The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. <b>2011</b> , 204, 193-201	832
445	Circulating angiogenic and antiangiogenic factors in women with eclampsia. <b>2011</b> , 204, 152.e1-9	63
444	Midpregnancy levels of angiogenic markers in relation to maternal characteristics. <b>2011</b> , 204, 244.e1-12	31
443	Fetal hemoglobin and $\beta_2$ -microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. <b>2011</b> , 204, 520.e1-5	52
442	Placental expression of angiogenic factors in Trisomy 13. <b>2011</b> , 204, 546.e1-4	14
441	Placental protein 13 (PP13/galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. <b>2011</b> , 205, 156.e1-14	42
440	Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. <b>2011</b> , 205, 469.e1-8	68
439	Pre-eclampsia: a maternal manifestation of a fetal adaptive response?. <b>2011</b> , 38, 367-70	10
438	Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. <b>2011</b> , 22, 1587-95	15
437	Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. <b>2011</b> , 9, 77	25
436	First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. <b>2011</b> , 31, 955-61	25

435	Preeclampsia: Effect on the Fetus and Newborn. <b>2011</b> , 12, e198-e206		27
434	Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. <b>2011</b> , 173, 630-9		60
433	Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. <b>2011</b> , 39, 641-52		172
432	Histidine-rich glycoprotein as an early biomarker of preeclampsia. <b>2011</b> , 24, 496-501		23
431	Biomarkers in Preeclampsia. <b>2011</b> , 385-426		2
430	Normal and Abnormal Early Pregnancy. <b>2011</b> , 5, 356-384		0
429	Polymorphisms in maternal and fetal genes encoding for proteins involved in extracellular matrix metabolism alter the risk for small-for-gestational-age. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2011</b> , 24, 362-80	2	15
428	Measurement of sVEGF R1 and PlGF in serum: comparing prototype assays from Beckman Coulter, Inc. to R&D Systems microplate assays. <i>Hypertension in Pregnancy</i> , <b>2011</b> , 30, 18-27	2	9
427	Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 1135-41	2	14
426	The vascular endothelial growth factor family in adverse pregnancy outcomes. <b>2012</b> , 18, 436-57		139
425	DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased gene expression. <b>2012</b> , 87, 81		56
424	Angiogenic imbalance and plasma lipid alterations in women with preeclampsia from a developing country. <b>2012</b> , 30, 158-66		12
423	Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. <b>2012</b> , 125, 911-9		411
422	The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. <b>2012</b> , 58, 837-45		89
421	Comparison of angiogenic and anti-angiogenic factors in maternal and umbilical cord blood in early- and late-onset pre-eclampsia. <b>2012</b> , 28, 628-32		14
420	Angiogenic factors and pregnant woman with new onset seizures. <i>Hypertension in Pregnancy</i> , <b>2012</b> , 31, 207-10	2	2
419	Magnesium sulfate therapy of preeclampsia: an old tool with new mechanism of action and prospect in management and prophylaxis. <b>2012</b> , 35, 1005-11		11
418	First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. <b>2012</b> , 27, 358-65		16



417	Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?. <b>2012</b> , 60, 239-46		70
416	Obstetric nephrology: preeclampsia--the nephrologist's perspective. <b>2012</b> , 7, 2107-13		13
415	Increased protein-coding mutations in the mitochondrial genome of African American women with preeclampsia. <b>2012</b> , 19, 1343-51		11
414	Preeclampsia and retinopathy of prematurity in preterm births. <b>2012</b> , 130, e101-7		38
413	Low VEGF expression in conceptus material and maternal serum AFP and hCG levels as indicators of defective angiogenesis in first-trimester miscarriages. <b>2012</b> , 13, 111-7		9
412	Renal evaluation in women with preeclampsia. <b>2012</b> , 2, 125-32		15
411	Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. <b>2012</b> , 30, 2173-81		37
410	Twin-to-twin transfusion syndrome. 145-155		
409	Expression of antiangiogenic factors in the placental structures in pre-eclampsia. <b>2012</b> , 154, 287-91		3
408	Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. <b>2012</b> , 23, 779-84		16
407	Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 498-507	2	104
406	Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 2651-7	2	53
405	Examining the correlation between placental and serum placenta growth factor in preeclampsia. <b>2012</b> , 207, 140.e1-6		20
404	Early pregnancy screening for hypertensive disorders in women without a-priori high risk. <b>2012</b> , 40, 398-405		15
403	Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. <b>2012</b> , 6, 121-30		13
402	Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. <b>2012</b> , 91, 1388-94		27
401	Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and preeclamptic pregnant women: a comparison between preeclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2012</b> , 25, 806-11	2	6
400	Chemerin is present in human cord blood and is positively correlated with birthweight. <b>2012</b> , 207, 412.e1-10		21

399	A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. <b>2012</b> , 2, 8-15	42
398	The Impact of Magnesium Sulfate Therapy on Angiogenic Factors in Preeclampsia. <b>2012</b> , 2, 16-21	5
397	Second trimester anti-angiogenic proteins and preeclampsia. <b>2012</b> , 2, 158-163	15
396	Linking preeclampsia and cardiovascular disease later in life. <b>2012</b> , 50, 985-93	27
395	Early-Onset Preeclampsia and HELLP Syndrome: An Overview. <b>2012</b> , 1867-1891	8
394	Prediction of preeclampsia by combining serum histidine-rich glycoprotein and uterine artery Doppler. <b>2012</b> , 25, 1305-10	11
393	Vascular Endothelial Growth Factor (VEGF) and soluble VEGF receptor 1 (sFlt-1) levels in early and mature human milk from mothers of preterm versus term infants. <b>2012</b> , 28, 522-8	15
392	A cohort evaluation on arterial stiffness and hypertensive disorders in pregnancy. <b>2012</b> , 12, 160	14
391	Immunologic Basis of Placental Function and Diseases. <b>2012</b> , 37-50	1
390	Maternal serum endoglin as an early marker of pre-eclampsia in high-risk patients. <b>2012</b> , 4, 521-5	7
389	Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. <b>2012</b> , 285, 891-9	8
388	First trimester serum markers to predict preeclampsia. <b>2012</b> , 162, 191-5	8
387	The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. <b>2012</b> , 206, 58.e1-8	251
386	Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. <b>2012</b> , 206, 163.e1-7	78
385	Perinatal risk factors for bronchopulmonary dysplasia in extremely low gestational age infants: a pregnancy disorder-based approach. <b>2012</b> , 160, 578-583.e2	33
384	Uteroplacental arterio-venous difference in soluble VEGFR-1 (sFlt-1), but not in soluble endoglin concentrations in preeclampsia. <b>2012</b> , 33, 224-6	6
383	Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. <b>2013</b> , 13, 110	50
382	Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?. <b>2013</b> , 287, 865-73	18

381	Can leukocyte count during the first trimester of pregnancy predict later gestational complications?. <b>2013</b> , 287, 421-7		13
380	Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. <b>2013</b> , 463, 445-58		34
379	The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. <b>2013</b> , 36, 3671-7		25
378	Measurement of placental bed vascularization in the first trimester, using 3D-power-Doppler, for the detection of pregnancies at-risk for fetal and maternal complications. <b>2013</b> , 34, 892-8		34
377	Identification of interleukin-1 beta, but no other inflammatory proteins, as an early onset pre-eclampsia biomarker in first trimester serum by bead-based multiplexed immunoassays. <b>2013</b> , 33, 1183-8		33
376	Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. <b>2013</b> , 208, 287.e1-287.e15		103
375	Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study. <b>2013</b> , 171, 225-30		27
374	Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. <b>2013</b> , 33, 149-55		12
373	Preeclampsia is associated with an elevation of plasma sMet concentrations in the second trimester. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 860-5	2	1
372	Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 1359-70	2	30
371	Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 116-22	2	4
370	The severity of hypoxic changes and oxidative DNA damage in the placenta of early-onset preeclamptic women and fetal growth restriction. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 491-6	2	53
369	Preeclampsia, gestational hypertension and subsequent hypothyroidism. <b>2013</b> , 3, 21-27		10
368	Maternal soluble fms-like tyrosine kinase-1, placental growth factor, plasminogen activator inhibitor-2, and folate concentrations and early fetal size: the Generation R study. <b>2013</b> , 209, 121.e1-11		15
367	Placental endoglin levels in diamniotic-monochorionic twin gestations: correlation with clinical and placental characteristics. <b>2013</b> , 34, 261-8		6
366	Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. <b>2013</b> , 208, 310.e1-310.e11		48
365	Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. <b>2013</b> , 3, 124-32		48
364	Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia. <b>2013</b> , 69, 105-23		15

363	New developments in the pathogenesis of preeclampsia. <b>2013</b> , 20, 265-70		72
362	Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?. <b>2013</b> , 120, 1183-91		67
361	Is there an association between platelet count during the first trimester and preeclampsia or other obstetric complications later in pregnancy?. <i>Hypertension in Pregnancy</i> , <b>2013</b> , 32, 74-82	2	13
360	The maternal HLA-G 1597C null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African-American women. <b>2013</b> , 19, 144-52		28
359	An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. <b>2013</b> , 2013, 202346		19
358	Serum concentration of antiangiogenic and angiogenic factors in subclasses of pre-eclampsia may be an evidence of their participation in its pathogenesis. <b>2013</b> , 3, 74-79		
357	Angiogenic factors in preeclampsia: potential for diagnosis and treatment. <b>2013</b> , 22, 643-50		24
356	Gestation dependant changes in angiogenic factors and their associations with fetal growth measures in normotensive pregnancy. <b>2013</b> , 8, e54153		39
355	The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. <b>2013</b> , 41, 511-6		47
354	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. <i>Hypertension in Pregnancy</i> , <b>2013</b> , 32, 189-201	2	106
353	Redefining preeclampsia using placenta-derived biomarkers. <b>2013</b> , 61, 932-42		259
352	Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. <b>2013</b> , 61, 1118-25		42
351	Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. <b>2013</b> , 19, 391-405		55
350	Midtrimester amniotic fluid concentrations of angiogenic factors in relation to maternal, gestational and neonatal characteristics in normal pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2013</b> , 26, 75-8	2	7
349	Recent advances in the understanding of the pathophysiology of preeclampsia. <b>2013</b> , 62, 666-73		91
348	Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. <i>Hypertension in Pregnancy</i> , <b>2013</b> , 32, 459-73	2	24
347	Association between physical activity in early pregnancy and markers of placental growth and function. <b>2013</b> , 35, 787-792		8
346	Changes in Structures and Relationships of Trophoblasts, Leukocytes, and Maternal Vessels in Implantation Sites to Midpregnancy. <b>2014</b> , 189-200		

345	Decreased seizure threshold in an eclampsia-like model induced in pregnant rats with lipopolysaccharide and pentylenetetrazol treatments. <b>2014</b> , 9, e89333		27
344	Antiretroviral therapy and preterm birth in HIV-infected women. <b>2014</b> , 12, 293-306		26
343	Maternal plasma soluble TRAIL is decreased in preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 217-27	2	13
342	Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 1854-9		32
341	Aspirin for prevention of preeclampsia in lupus pregnancy. <b>2014</b> , 2014, 920467		30
340	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. <i>Hypertension in Pregnancy</i> , <b>2014</b> , 33, 427-39	2	28
339	The anti-aging factor Eklotho during human pregnancy and its expression in pregnancies complicated by small-for-gestational-age neonates and/or preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 449-57	2	13
338	Angiogenic factors vs Doppler surveillance in the prediction of adverse outcome among late-pregnancy small-for-gestational-age fetuses. <b>2014</b> , 43, 533-40		46
337	Vascular dysfunction in preeclampsia. <b>2014</b> , 21, 4-14		101
336	Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. <b>2014</b> , 35, 855-65		63
335	Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 132-44	2	55
334	A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. <b>2014</b> , 37, 753-8		47
333	Altered methylation and expression patterns of genes regulating placental angiogenesis in preterm pregnancy. <b>2014</b> , 21, 1508-17		27
332	Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy. <b>2014</b> , 90, 42		10
331	Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 1038-48	2	33
330	Placental pathology in early-onset and late-onset fetal growth restriction. <b>2014</b> , 36, 117-28		171
329	Levels of maternal serum angiogenic factors in third-trimester normal pregnancies: reference ranges, influence of maternal and pregnancy factors and fetoplacental Doppler indices. <b>2014</b> , 36, 38-43		7
328	Prediction of preeclampsia and induced delivery at . <b>2014</b> , 14, 292		23

327	ANGIOGENIC IMBALANCES IN THE PATHOGENESIS OF PREGNANCY COMPLICATIONS. <b>2014</b> , 25, 42-58		
326	Gestational diabetes and hypertensive disorders of pregnancy as vascular risk signals: an overview and grading of the evidence. <b>2014</b> , 30, 765-73		47
325	Human chorionic gonadotropin, angiogenic factors, and preeclampsia risk: a nested case-control study. <b>2014</b> , 93, 454-62		17
324	Prediction of preeclampsia-bench to bedside. <b>2014</b> , 16, 491		8
323	Angiogenic factors in diagnosis, management, and research in preeclampsia. <b>2014</b> , 63, 198-202		89
322	Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia. <b>2014</b> , 44, 402-10		11
321	Use of first or second trimester serum markers, or both, to predict preeclampsia. <b>2014</b> , 4, 271-8		11
320	Pre-eclampsia part 1: current understanding of its pathophysiology. <b>2014</b> , 10, 466-80		585
319	Maternal/newborn VEGF-C936T interaction and its influence on the risk, severity and prognosis of preeclampsia, as well as on the maternal angiogenic profile. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2014</b> , 27, 1754-60	2	18
318	Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. <b>2014</b> , 182, 194-201		62
317	Second- and third-trimester biochemical and ultrasound markers predictive of ischemic placental disease. <b>2014</b> , 38, 167-76		12
316	Angiogenic factors at diagnosis of late-onset small-for-gestational age and histological placental underperfusion. <b>2014</b> , 35, 398-403		50
315	Angiogenic and inflammatory biomarkers in midpregnancy and small-for-gestational-age outcomes in Tanzania. <b>2014</b> , 211, 509.e1-8		26
314	SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. <b>2015</b> , 55, e1-29		122
313	Urine proteomic studies in preeclampsia. <b>2015</b> , 9, 501-6		12
312	Combination of PAPP <sub>A</sub> , fhCG $\beta$ AFP, PlGF, sTNFR1, and Maternal Characteristics in Prediction of Early-onset Preeclampsia. <b>2015</b> , 9, 13-20		20
311	Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. <b>2015</b> , 45, 241-6		148
310	Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. <b>2015</b> , 10, e0119547		28

309	Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. <b>2015</b> , 10, e0126815	36
308	Maternal Serum Meteorin Levels and the Risk of Preeclampsia. <b>2015</b> , 10, e0131013	5
307	Maternal Smoking History Enhances the Expression of Placental Growth Factor in Invasive Trophoblasts at Early Gestation Despite Cessation of Smoking. <b>2015</b> , 10, e0134181	3
306	Midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor in pregnant women who subsequently develop preeclampsia. <b>2015</b> , 58, 10-6	8
305	Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia?. <b>2015</b> , 447, 34-8	42
304	Placental growth factor concentration in maternal circulation decreases after fetal death: lessons from a case series study. <b>2015</b> , 292, 1027-32	2
303	Prediction of Fetal Growth Restriction by Analyzing the Messenger RNAs of Angiogenic Factor in the Plasma of Pregnant Women. <b>2015</b> , 22, 743-9	7
302	Biochemical markers of placental dysfunction in assisted conception. <b>2015</b> , 18, 282-90	4
301	A prior placenta accreta is an independent risk factor for post-partum hemorrhage in subsequent gestations. <b>2015</b> , 187, 20-4	10
300	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. <b>2015</b> , 35, 386-93	25
299	Maternal serum sFlt-1/PLGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. <b>2015</b> , 45, 286-93	41
298	Exposure to experimental preeclampsia in mice enhances the vascular response to future injury. <b>2015</b> , 65, 863-70	53
297	Update on the pathophysiological implications and clinical role of angiogenic factors in pregnancy. <b>2015</b> , 37, 81-92	47
296	Angiogenic biomarkers in pregnancy: defining maternal and fetal health. <b>2015</b> , 94, 820-32	19
295	Updates in Preeclampsia. <b>2015</b> , 5, 74-81	0
294	Maternal serum concentrations of s-Endoglin and IL-6 in pregnancy complicated by preterm premature membrane rupture. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 1957-62	2 4
293	Baseline placental growth factor levels for the prediction of benefit from early aspirin prophylaxis for preeclampsia prevention. <b>2015</b> , 5, 280-6	7
292	Early pregnancy maternal and fetal angiogenic factors and fetal and childhood growth: the Generation R Study. <b>2015</b> , 30, 1302-13	17

291	Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies. <b>2015</b> , 42, 1141-9		28
290	Maternal circulating angiogenic factors in twin and singleton pregnancies. <b>2015</b> , 212, 636.e1-8		27
289	Pre-eclampsia: A Multifaceted Disorder of Pregnancy. <b>2015</b> , 347-358		
288	Pathogenesis of preeclampsia. <b>2015</b> , 24, 131-8		135
287	Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1. <b>2015</b> , 36, 446-53		44
286	Concentrations of eNOS, VEGF, ACE and PlGF in maternal blood as predictors of impaired fetal growth in pregnancy complicated by gestational hypertension/preeclampsia. <i>Hypertension in Pregnancy</i> , <b>2015</b> , 34, 17-23	2	7
285	Accuracy of angiogenic biomarkers at 20weeks' gestation in predicting the risk of pre-eclampsia: A WHO multicentre study. <b>2015</b> , 5, 330-8		39
284	Gestational Diabetes and Maternogenic Preeclampsia: By-products of the Accelerated Metabolic Syndrome in Pregnancy. <b>2015</b> , 135-150		
283	Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. <b>2015</b> , 132, 1726-33		63
282	Maternal plasma fetuin-A concentration is lower in patients who subsequently developed preterm preeclampsia than in uncomplicated pregnancy: a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2015</b> , 28, 1260-1269	2	3
281	Evaluation of first trimester serum soluble endothelial cell-specific tyrosine kinase receptor in normal and affected pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2015</b> , 28, 1815-21	2	1
280	Placenta-derived angiogenic proteins and their contribution to the pathogenesis of preeclampsia. <b>2015</b> , 18, 115-23		34
279	Tests to Predict Preeclampsia. <b>2015</b> , 221-251		2
278	Angiogenesis and Preeclampsia. <b>2015</b> , 113-132		3
277	Current best practice in the management of hypertensive disorders in pregnancy. <b>2016</b> , 9, 79-94		85
276	Pre-eclampsia: its pathogenesis and pathophysiology. <b>2016</b> , 27, 71-8		170
275	Are We Getting Closer to Explaining Preeclampsia?. <b>2016</b> , 5, 264-272		
274	Bone Marrow-Derived Endothelial Progenitor Cells Reduce Recurrent Miscarriage in Gestation. <b>2016</b> , 25, 2187-2197		4



273	FGF1 and FGF2 mutations in preeclampsia and related features. <b>2016</b> , 43, 81-5		11
272	The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia. <b>2016</b> , 30, 788-793		7
271	Angiogenic Factors and Doppler Evaluation in Normally Growing Fetuses at Routine Third-Trimester Scan: Prediction of Subsequent Low Birth Weight. <b>2016</b> , 40, 13-20		22
270	Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. <b>2016</b> , 42, 1-8		123
269	Preeclampsia/Eclampsia candidate genes show altered methylation in maternal leukocytes of preeclamptic women at the time of delivery. <i>Hypertension in Pregnancy</i> , <b>2016</b> , 35, 394-404	2	13
268	Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. <b>2016</b> , 67, 1263-72		67
267	Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia. <b>2016</b> , 42, 44-50		13
266	A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients. <b>2016</b> , 66, 98-103		3
265	Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. <b>2016</b> , 67, 1273-80		43
264	Preeclampsia: a fascinating syndrome due not only to oxidative stress. <b>2016</b> , 35, 477-8		
263	Preeclampsia: A fascinating syndrome due not only to oxidative stress. <b>2016</b> , 35, 477-478		
262	Sex differences in early growth during the first three years of life in offspring from mothers with pregnancy-induced hypertension. <b>2016</b> , 6, 361-366		5
261	In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. <b>2016</b> , 215, 782.e1-782.e9		27
260	Possible Common Aetiology behind Maternal Preeclampsia and Congenital Heart Defects in the Child: a Cardiovascular Diseases in Norway Project Study. <b>2016</b> , 30, 76-85		31
259	Placental endoplasmic reticulum stress negatively regulates transcription of placental growth factor via ATF4 and ATF6 implications for the pathophysiology of human pregnancy complications. <b>2016</b> , 238, 550-61		63
258	Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. <b>2016</b> , 77, 361-431		114
257	Angiopoyetina-1 plasmática en el segundo trimestre como predictor del desarrollo de preeclampsia. <b>2016</b> , 30, 109-114		
256	Pregnancy in Women With CKD: A Success Story. <b>2016</b> , 68, 633-639		24

255	Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. <b>2016</b> , 214, 629.e1-629.e17		65
254	Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. <b>2016</b> , 47, 324-31		30
253	Placental growth factor deficiency is associated with impaired cerebral vascular development in mice. <b>2016</b> , 22, 130-42		36
252	Placental growth factor and vascular endothelial growth factor serum levels in Tunisian Arab women with suspected preeclampsia. <b>2016</b> , 79, 1-6		14
251	Down-regulation of placental neuropilin-1 in fetal growth restriction. <b>2016</b> , 214, 279.e1-279.e9		13
250	Supplementation of maternal omega-3 fatty acids to pregnancy induced hypertension Wistar rats improves IL10 and VEGF levels. <b>2016</b> , 104, 25-32		22
249	Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. <b>2016</b> , 67, 740-7		100
248	High-throughput deep screening and identification of four peripheral leucocyte microRNAs as novel potential combination biomarkers for preeclampsia. <b>2016</b> , 36, 263-7		5
247	Cardio-renal consequences of low birth weight and preterm birth. <b>2016</b> , 41, 83-88		2
246	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. <b>2016</b> , 214, 108.e1-108.e14		96
245	The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 1214-28	2	42
244	Assessment of angiogenesis modulators in pregnant women with pre-eclampsia: a case-control study. <b>2016</b> , 293, 369-75		15
243	Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 537-43	2	16
242	Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2016</b> , 29, 855-62	2	36
241	Early pregnancy angiogenic proteins levels and pregnancy related hypertensive disorders. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 534-539	2	6
240	Dose-response association between maternal body mass index and small for gestational age: a meta-analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 213-218	2	7
239	Changes in uterine artery Doppler velocimetry and circulating angiogenic factors in the first half of pregnancies delivering a small-for-gestational-age neonate. <b>2017</b> , 49, 357-363		16
238	Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia. <b>2017</b> , 50, 93-99		14

237	Is an episode of suspected preterm labor that subsequently leads to a term delivery benign?. <b>2017</b> , 216, 89-94	15
236	Anti-angiogenesis and Preeclampsia in 2016. <b>2017</b> , 19, 6	17
235	A prospective study on first trimester prediction of ischemic placental diseases. <b>2017</b> , 37, 341-349	4
234	The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study. <b>2017</b> , 217, 67.e1-67.e21	49
233	Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. <b>2017</b> , 217, 282-302	139
232	Angiogenic and Antiangiogenic Markers for Prediction and Risk Classification of Preeclampsia. <b>2017</b> , 60, 134-140	10
231	Independent risk factors for a small placenta and a small-for-gestational-age infant at 35-41 weeks of gestation: An association with circulating angiogenesis-related factor levels at 19-31 weeks of gestation. <b>2017</b> , 43, 1285-1292	2
230	Multiple Soluble TGF- $\beta$ Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF- $\beta$ Signaling. <b>2017</b> , 102, 3065-3074	8
229	Prediction of fetal growth restriction using estimated fetal weight vs a combined screening model in the third trimester. <b>2017</b> , 50, 603-611	28
228	Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosclerosis in the basal plate of the placenta. <b>2017</b> , 216, 287.e1-287.e16	81
227	Biomarkers in Preeclampsia. <b>2017</b> , 555-594	2
226	FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. <b>2017</b> , 7, 12139	23
225	Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. <b>2017</b> , 217, 684.e1-684.e17	32
224	The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PIGF/sVEGFR-1 ratio). <b>2017</b> , 217, 682.e1-682.e13	19
223	Angiogenic, Antiangiogenic Molecules, and Bioactive Lipids in Preeclampsia. <b>2017</b> , 30, 864-870	3
222	Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. <b>2017</b> , 37, 386-397	115
221	Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. <b>2017</b> , 148, 87-165	111
220	Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles. <b>2017</b> , 7, 5887	34

219	Thyroid disease in pregnancy: new insights in diagnosis and clinical management. <b>2017</b> , 13, 610-622		152
218	Influences of placental growth factor on mouse retinal vascular development. <b>2017</b> , 246, 700-712		8
217	Vascular endothelial growth factor single nucleotide polymorphisms and haplotypes in pre-eclampsia: A case-control study. <b>2017</b> , 97, 175-180		11
216	Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. <b>2017</b> , 40, 305-310		68
215	Placental gene expression of the placental growth factor (PLGF) in intrauterine growth restriction. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 1471-1475	2	9
214	Performance of third-trimester combined screening model for prediction of adverse perinatal outcome. <b>2017</b> , 50, 353-360		21
213	Pathophysiology of Preeclampsia. <b>2017</b> , 1724-1732.e2		
212	Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study. <b>2017</b> , 60, 154-162		17
211	Understanding biological mechanisms underlying adverse birth outcomes in developing countries: protocol for a prospective cohort (AMANHI bio-banking) study. <b>2017</b> , 7, 021202		18
210	A Systematic Review of Placental Biomarkers Predicting Small-for-Gestational-Age Neonates. <b>2018</b> , 20, 272-283		6
209	Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. <b>2018</b> , 225, 26-34		26
208	An sFlt-1:PLGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia. <b>2018</b> , 11, 54-60		14
207	Cadmium disrupts signaling of the hypoxia-inducible (HIF) and transforming growth factor (TGF- $\beta$ ) pathways in placental JEG-3 trophoblast cells via reactive oxygen species. <b>2018</b> , 342, 108-115		10
206	Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. <b>2018</b> , 218, S725-S737		64
205	Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. <b>2018</b> , 218, 211-218		33
204	HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation. <b>2018</b> , 8, 6552		24
203	The Role of Interleukin-10 in the Pathophysiology of Preeclampsia. <b>2018</b> , 20, 36		25
202	sFlt-1/PLGF. <b>2018</b> , 175-198		

201	Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia. <b>2018</b> , 14, 245-251		4
200	Is 8% O2 more normoxic than 21% O2 for long-term in vitro cultures of human primary term cytotrophoblasts?. <b>2018</b> , 24, 211-220		6
199	The predictive value of the sFlt-1/PLGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies. <b>2018</b> , 14, 222-227		16
198	Novel Therapies for Preeclampsia. <b>2018</b> , 227-237		
197	Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia. <b>2018</b> , 51, 387-395		19
196	Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2018</b> , 31, 418-432	2	17
195	Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age. <b>2018</b> , 43, 250-265		8
194	Angiogenic and antiangiogenic factors in preeclampsia. <b>2018</b> , 214, 7-14		34
193	Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. <b>2018</b> , 71, 306-316		83
192	Angiogenic factors: potential to change clinical practice in pre-eclampsia?. <b>2018</b> , 125, 1389-1395		36
191	An updated view on the origin and use of angiogenic biomarkers for preeclampsia. <b>2018</b> , 18, 1053-1061		10
190	Antenatal placental assessment in the prediction of adverse pregnancy outcome after reduced fetal movement. <b>2018</b> , 13, e0206533		13
189	New highly sensitive sandwich ELISA system for soluble endoglin quantification in different biological fluids. <b>2018</b> , 78, 515-523		5
188	Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 'weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. <b>2018</b> , 18, 354		15
187	Preeclampsia predicts higher incidence of bronchopulmonary dysplasia. <b>2018</b> , 38, 1165-1173		7
186	Maternal one carbon metabolism through increased oxidative stress and disturbed angiogenesis can influence placental apoptosis in preeclampsia. <b>2018</b> , 206, 61-69		20
185	Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort. <b>2018</b> , 14, 252-259		5
184	Pregnancy and the Kidney. <b>2018</b> , 319-345		2

183	Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns. <b>2018</b> , 2018, 2632637	15
182	Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam. <b>2018</b> , 14, 37-42	6
181	Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. <b>2018</b> , 9, 973	81
180	Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1661	8.4 79
179	First Trimester Combined Screening Algorithms for Fetal Growth Restriction. <b>2018</b> , 95-104	
178	Development, Function, and Pathology of the Placenta. <b>2018</b> , 40-60.e8	0
177	Increases in placental nitric oxide, but not nitric oxide-mediated relaxation, underlie the improvement in placental efficiency and antihypertensive effects of hydrogen sulphide donor in hypertensive pregnancy. <b>2018</b> , 45, 1118-1127	7
176	Role of vitamin D in influencing angiogenesis in preeclampsia. <i>Hypertension in Pregnancy</i> , <b>2019</b> , 38, 201-207	11
175	Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia. <b>2019</b> , 461, 159-170	9
174	Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. <b>2019</b> , 39, 947-957	6
173	Placental Galectins Are Key Players in Regulating the Maternal Adaptive Immune Response. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1240	8.4 25
172	A Review of Angiogenic Imbalance in HIV-Infected Hypertensive Disorders of Pregnancy. <b>2019</b> , 21, 69	3
171	Hypertensive Disorders of Pregnancy. <b>2019</b> , 37, 345-354	24
170	Twin-to-Twin Transfusion Syndrome: Placental and Fetal Pathogenesis. <b>2019</b> , 344-352	
169	Circulating soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor during pregnancy in normotensive women in KwaZulu-Natal, South Africa. <b>2019</b> , 19, 1821-1832	1
168	The REVAMP study: research exploring various aspects and mechanisms in preeclampsia: study protocol. <b>2019</b> , 19, 308	5
167	Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. <b>2019</b> , 74, 991-997	34
166	Effect of Low-Dose Aspirin on Soluble FMS-Like Tyrosine Kinase 1/Placental Growth Factor (sFlt-1/PlGF Ratio) in Pregnancies at High Risk for the Development of Preeclampsia. <b>2019</b> , 8,	6

165	Maternal vascular malformation in the placenta is an indicator for fetal growth restriction irrespective of neonatal birthweight. <b>2019</b> , 87, 8-15		7
164	Longitudinal changes in placental biomarkers in women with early versus late placental dysfunction. <i>Hypertension in Pregnancy</i> , <b>2019</b> , 38, 268-277	2	1
163	Early malaria infection, dysregulation of angiogenesis, metabolism and inflammation across pregnancy, and risk of preterm birth in Malawi: A cohort study. <b>2019</b> , 16, e1002914		19
162	The role of angiogenic factors in the management of preeclampsia. <b>2019</b> , 98, 700-707		17
161	Maternal Flt-1 and endoglin expression by circulating monocyte subtype and polarization in preeclampsia and fetal growth restriction. <b>2019</b> , 3, 100024		0
160	The prediction of early preeclampsia: Results from a longitudinal proteomics study. <b>2019</b> , 14, e0217273		41
159	Can Fetal Growth Velocity and First Trimester Maternal Biomarkers Improve the Prediction of Small-for-Gestational Age and Adverse Neonatal Outcome?. <b>2019</b> , 46, 274-284		5
158	Preeclampsia: Pathophysiology, Challenges, and Perspectives. <b>2019</b> , 124, 1094-1112		415
157	Relationships of serum placental growth factor and soluble fms-like tyrosine kinase-1 with fetal and uterine artery Doppler indices in pre-eclampsia. <b>2019</b> , 145, 176-181		2
156	Placental growth factor blunts uterine artery responses to angiotensin II. <b>2019</b> , 126, 1058-1064		3
155	Pre-eclampsia: pathogenesis, novel diagnostics and therapies. <b>2019</b> , 15, 275-289		259
154	Angiogenic factors during pregnancy in Asian women with elevated blood pressure in early pregnancy and the risk of preeclampsia: a longitudinal cohort study. <b>2019</b> , 9, e032237		4
153	Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. <b>2019</b> , 5, CD012245		12
152	No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study. <b>2019</b> , 19, 482		3
151	Urinary Placental Growth Factor for Prediction of Placental Adverse Outcomes in High-Risk Pregnancies. <b>2019</b> , 134, 1326-1332		5
150	The human placental proteome secreted into the maternal and fetal circulations in normal pregnancy based on 4-vessel sampling. <b>2019</b> , 33, 2944-2956		15
149	Molecular determinants of microvascular dysfunction in hypertensive pregnancy and preeclampsia. <b>2018</b> , 26, e12508		9
148	Carotid arterial wall stiffness correlates positively with impedance of the umbilical and uterine arteries in women with preeclampsia. <b>2019</b> , 47, 27-35		3

147	Accelerated growth of hemangioblastoma in pregnancy: the role of proangiogenic factors and upregulation of hypoxia-inducible factor (HIF) in a non-oxygen-dependent pathway. <b>2019</b> , 42, 209-226		9
146	Validation of Fetal Medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 286-292	2	16
145	Evaluation of agreement of placental growth factor (PLGF) tests and the soluble FMS-like tyrosine kinase 1 (sFlt-1)/PLGF ratio, comparison of predictive accuracy for pre-eclampsia, and relation to uterine artery Doppler and response to aspirin. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 179-187	2	8
144	Do the physiological aging of the placenta and the changes in angiogenesis marker sFlt-1 and PLGF concentrations predispose patients to late-onset preeclampsia?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 11-20	2	9
143	The profiles of soluble adhesion molecules in the "great obstetrical syndromes". <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2019</b> , 32, 2113-2136	2	14
142	Biology of preeclampsia: Combined actions of angiogenic factors, their receptors and placental proteins. <b>2020</b> , 1866, 165349		11
141	ELABELA plasma concentrations are increased in women with late-onset preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2020</b> , 33, 5-15	2	26
140	Hypertension in Pregnancy. <b>2020</b> , 455-483		
139	A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PLGF ratio and NT-proBNP as biomarkers. <b>2020</b> , 58, 399-407		4
138	Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2021</b> , 34, 3463-3474	2	16
137	The role of biomarkers in predicting pre-eclampsia in high-risk women. <b>2020</b> , 57, 128-137		2
136	The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia. <b>2020</b> ,		12
135	Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia. <b>2020</b> , 76, 875-883		10
134	sFlt-1/PLGF ratio for the prediction of delivery within 48 hours and adverse outcomes in expectantly managed early-onset preeclampsia. <b>2020</b> , 22, 17-23		6
133	Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world. <b>2020</b> , 182, 114247		5
132	"Screening for small-for-gestational age neonates at early third trimester in a high-risk population for preeclampsia". <b>2020</b> , 20, 563		1
131	Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. <b>2020</b> ,		28
130	Utility of biochemical tests in prediction, diagnostics and clinical management of preeclampsia: a review. <b>2020</b> , 16, 1370-1375		2



129	Placental abruption as a trigger of DIC in women with HELLP syndrome: a population-based study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2020</b> , 1-11	2	5
128	Temperature and preeclampsia: Epidemiological evidence that perturbation in maternal heat homeostasis affects pregnancy outcome. <b>2020</b> , 15, e0232877		12
127	Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study. <b>2021</b> , 38, 1472-1479		4
126	Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: A case series study. <b>2020</b> , 99, 994-1002		5
125	Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia. <b>2020</b> , 20, 80		13
124	Angiogenesis biomarkers for the prediction of severe adverse outcomes in late-preterm preeclampsia. <b>2020</b> , 19, 74-80		2
123	Maternal Serum Placental Growth Factor, Soluble Fms-Like Tyrosine Kinase-1, and Soluble Endoglin in Twin Gestations and the Risk of Preeclampsia-A Systematic Review. <b>2020</b> , 9,		4
122	An Insight into the Angiogenic and Lymphatic Interplay in Pre-eclampsia Comorbid with HIV Infection. <b>2020</b> , 22, 35		1
121	Anti-phospholipid antibodies and reproductive failures. <b>2021</b> , 85, e13258		6
120	Combining early (. <b>2021</b> , 24, 37-47		
119	Subfoveal Choroidal Thickness and Associated Changes of Angiogenic Factors in Women with Severe Preeclampsia. <b>2021</b> , 38, 482-489		3
118	Low placental growth factor levels and high soluble endoglin levels at 26-31 weeks of gestation precede light placenta with and without relatively heavy infant, respectively: A retrospective cohort study. <b>2021</b> , 47, 1040-1051		
117	Predictive Accuracy of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for Preeclampsia in Japan: A Systematic Review. <b>2021</b> , 9, 1-7		
116	Maternal plasma soluble neuropilin-1 is downregulated in fetal growth restriction complicated by abnormal umbilical artery Doppler: a pilot study. <b>2021</b> , 58, 716-721		
115	Effect of Fas/FasL signaling pathway activation in trophoblasts on recurrent spontaneous abortion. <b>2021</b> , 47, 1978-1986		
114	Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. <b>2021</b> , 23, 97-103		2
113	Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study.. <b>2022</b> , 226, 126.e1-126.e22		2
112	Unravelling the potential of angiogenic factors for the early prediction of preeclampsia. <b>2021</b> , 44, 756-769		1

111	How to define late fetal growth restriction. <b>2021</b> , 73, 409-414		
110	Use of FMF algorithm for prediction of preeclampsia in high risk pregnancies: a single center longitudinal study. <i>Hypertension in Pregnancy</i> , <b>2021</b> , 40, 171-179	2	0
109	Maternal Immune System and State of Inflammation Dictate the Fate and Severity of Disease in Preeclampsia. <b>2021</b> , 2021, 9947884		1
108	Effects of preconception antiretroviral therapy in placenta development and pregnancy outcomes. <b>2021</b> , 35, 1139-1141		
107	Chronic hypertension and superimposed preeclampsia: screening and diagnosis.. <b>2022</b> , 226, S1182-S1195		1
106	Physiopathology of late-onset fetal growth restriction. <b>2021</b> , 73, 392-408		0
105	Healthy and preeclamptic pregnancies show differences in Guanylate-Binding Protein-1 plasma levels. <b>2021</b> , 25, 18-24		0
104	Risk factors for needing postpartum antihypertensive medications with hypertensive disorders: Timing of diagnosis, presence of proteinuria, and severity of disease. <b>2021</b> , 25, 175-178		0
103	Association of mid-trimester maternal angiogenic biomarkers with small-for-gestational-age infants in an urban Zambian cohort: a nested case-control study. <b>2021</b> ,		
102	Accurate Prediction of Total PlGF (Placental Growth Factor) From Free PlGF and sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1): Evidence for Markedly Elevated PlGF Levels in Women With Acute Fatty Liver of Pregnancy. <b>2021</b> , 78, 489-498		2
101	Developing a model of placental lesions prediction in varicose veins patients. <b>2021</b> , 18, 327-339		
100	Physiopathology. <b>2019</b> , 41-64		1
99	Hypertensive Disorders in Pregnancy. <b>2020</b> , 11-23		1
98	Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. <b>2008</b> , 3, e2766		43
97	Circulating soluble endoglin levels in pregnant women in Cameroon and Malawi--associations with placental malaria and fetal growth restriction. <b>2011</b> , 6, e24985		29
96	Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis. <b>2012</b> , 7, e29660		31
95	Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. <b>2012</b> , 7, e50208		57
94	Evaluation of current and new biomarkers in severe preeclampsia: a microarray approach reveals the VSIG4 gene as a potential blood biomarker. <b>2013</b> , 8, e82638		23

93	In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. <b>2014</b> , 9, e110867	21
92	Semaphorin 3F expression is reduced in pregnancy complicated by preeclampsia. An observational clinical study. <b>2017</b> , 12, e0174400	8
91	The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. <b>2017</b> , 12, e0181468	52
90	Effects of Maternal Obesity and Gestational Diabetes Mellitus on the Placenta: Current Knowledge and Targets for Therapeutic Interventions. <b>2021</b> , 19, 176-192	4
89	Vitamin D: effects on pregnancy, maternal, fetal and postnatal outcomes. <b>2018</b> , 90, 115-127	6
88	Expression of placental growth factor mRNA in preeclampsia. <b>2017</b> , 15, 169-174	3
87	Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. <b>2016</b> , 20, 1-160	22
86	A brief overview of preeclampsia. <b>2014</b> , 6, 1-7	91
85	Evaluation of Progesterone and Ovulation-stimulating Drugs on the Glandular Epithelium and Angiogenesis in Mice. <b>2017</b> , 6, 116	2
84	Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia. <b>2013</b> , 24, 174-9	25
83	Placental expression of miR-21-5p, miR-210-3p and miR-141-3p: relation to human fetoplacental growth. <b>2021</b> ,	0
82	C1431T Variant of PPAR $\alpha$ Associated with Preeclampsia in Pregnant Women. <b>2021</b> , 11,	2
81	Statins to prevent or treat preeclampsia: sometimes it is too late. <b>2021</b> ,	1
80	NLRP3 Activation and Its Relationship to Endothelial Dysfunction and Oxidative Stress: Implications for Preeclampsia and Pharmacological Interventions. <b>2021</b> , 10,	7
79	Hypertension. <b>2011</b> , 599-626.e8	1
78	Hypertension. <b>2011</b> , 239-275	
77	New aspect in management of fetal growth restriction. <b>2011</b> , 54, 1	
76	The association of serum placental growth factor with pregnancies complicated by preeclampsia and small for gestational age. <b>2012</b> , 55, 797	

- 75 Prediction of preeclampsia using angiogenic and antiangiogenic factors. **2013**, 1, 66-70
- 74 F. **2013**, 477-520
- 73 The potential of placental growth factor in the diagnosis and management of pre-eclampsia. **2013**, 8, 305-307
- 72 Altered Level of Soluble fms-like Tyrosine Kinase 1 (sFlt1) and Hypoxia Inducible Factor-1alpha (HIF-1alpha) in Normotensive Pregnancy and Preeclampsia. **2013**, 5, 121
- 71 Vascular endothelial growth factor role in predicting vascular disorders in pregnant with fetal growth restriction syndrome. **2015**, 96, 220-223 3
- 70 Prediction of Preeclampsia: Role of Antiangiogenic and Proangiogenic Biomarkers. **2017**, 9, 47-52
- 69 VEGF 121 Rekombinan Dapat Memperbaiki Endoteliosis Gromerular pada Mencit Bunting Model Preeklampsia. **2018**, 24, 19
- 68 Wider reference ranges of serum thyroid stimulating hormone in pregnant Korean women: is it time to stop overtreatment?. **2018**, 33, 493-496
- 67 Pro- to Anti-angiogenic Ratio in Preeclampsia. **2019**, 15, 137-142 1
- 66 Preeclampsia features in pregnancy with gestational diabetes mellitus. **2019**, 68, 19-36 1
- 65 Predictive values of clinical parameters and biophysical and biochemical markers in the first trimester for the detection of small-for-gestational age fetuses. **2020**, 49, 73-79
- 64 Case finding of early pregnancies at risk of preeclampsia using maternal blood leptin/ceramide ratio: multi-omics discovery and validation from a longitudinal study.
- 63 Response to letter to the editor. **2021**, 27, 6-7
- 62 Biochemical markers for prediction of preclampsia: review of the literature. **2011**, 5, 69-77 14
- 61 Biomarkers for the management of pre-eclampsia in pregnant women. **2013**, 138, 60-7 6
- 60 The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. **2015**, 13, 251-62 15
- 59 Expression of placental growth factor mRNA in preeclampsia. **2017**, 15, 169-174 2
- 58 Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia. **2019**, 13, 56-69 6

57	Early-pregnancy prediction of risk for pre-eclampsia using maternal blood leptin/ceramide ratio: discovery and confirmation. <b>2021</b> , 11, e050963		2
56	Performance of a validated spontaneous preterm delivery predictor in South Asian and Sub-Saharan African women: a nested case control study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2021</b> , 1-9		2
55	Angiogenesis and Preeclampsia. <b>2022</b> , 165-185		
54	Identification of key genes in pathogenesis of placental insufficiency intrauterine growth restriction.. <b>2022</b> , 22, 77		0
53	Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia.. <b>2022</b> ,		0
52	Circulating s-Endoglin concentrations in non-obese patients with gestational diabetes mellitus.. <b>2022</b> , 1-6		0
51	New approaches in predicting and diagnosing preeclampsia: Congo Red Dot Paper Test (Review).. <b>2022</b> , 23, 270		
50	The etiology of preeclampsia.. <b>2022</b> , 226, S844-S866		9
49	Preeclampsia and eclampsia: the conceptual evolution of a syndrome.. <b>2022</b> , 226, S786-S803		7
48	Longitudinal changes in serum immune markers during normal pregnancy in a North-Indian population.. <b>2022</b> , e13531		0
47	Reduced volumetric parameters of the placenta and extravillous trophoblastic cells in complicated pregnancies may lead to intrauterine growth restriction and small for gestational age birth.. <b>2022</b> ,		
46	Prenatal prediction of very late onset small-for-gestational age newborns in low-risk pregnancies.. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2022</b> , 1-5		2
45	Early pathways, biomarkers, and four distinct molecular subclasses of preeclampsia: The intersection of clinical, pathological, and high-dimensional biology studies.. <b>2022</b> ,		3
44	Birth weight and isolated congenital heart defects- a systematic review and meta-analysis.. <b>2022</b> ,		0
43	The Placental Innate Immune System Is Altered in Early-Onset Preeclampsia, but Not in Late-Onset Preeclampsia.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 780043	8.4	1
42	Clinical biomarkers of placental development. 188-200		
41	Data_Sheet_1.zip. <b>2018</b> ,		
40	Image_1.pdf. <b>2018</b> ,		

39 Image\_10.pdf. **2018**,

38 Image\_11.pdf. **2018**,

37 Image\_12.pdf. **2018**,

36 Image\_13.pdf. **2018**,

35 Image\_2.pdf. **2018**,

34 Image\_3.pdf. **2018**,

33 Image\_4.pdf. **2018**,

32 Image\_5.pdf. **2018**,

31 Image\_6.pdf. **2018**,

30 Image\_7.pdf. **2018**,

29 Image\_8.pdf. **2018**,

28 Image\_9.pdf. **2018**,

27 Presentation\_1.pdf. **2019**,

26 Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort.. *Hypertension in Pregnancy*, **2022**, 1-14 2 1

25 Placenta-derived proteins across gestation in healthy pregnancies— novel approach to assess placental function?. *BMC Medicine*, **2022**, 20, 11.4 1

24 Pentoxifylline as a therapeutic option for preeclampsia: a study on its placental effects.. *British Journal of Pharmacology*, 8.6

23 Obstetric and perinatal pathology in pregnant women who had complications from the group of the Great Obstetrical Syndromes. **2022**, 59-65 2

22 Circulating levels of transforming growth factor beta-1, 2 and 3 in HIV associated preeclamptic pregnancies. 1-7

21	Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. <b>2022</b> , 227, 615.e1-615.e25	3
20	Conventional Natural Killer cells control vascular remodeling in the uterus during pregnancy by acidifying the extracellular matrix with a2V.	0
19	Human Plasma Proteome During Normal Pregnancy.	0
18	Diagnostic biomolecules and combination therapy for pre-eclampsia. <b>2022</b> , 20,	0
17	Preeclampsia as a risk factor for the development of retinopathy of premature. <b>2022</b> , 17, 39-44	0
16	Angiogenic factors assessment in pre-eclampsia high risk population for the prediction of small-for-gestational age neonates: A prospective longitudinal study.	0
15	Molecular subclasses of preeclampsia characterized by a longitudinal maternal proteomics study: distinct biomarkers, disease pathways and options for prevention. <b>2022</b> ,	0
14	Preeclampsia at term can be classified into two clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood. <b>2022</b> ,	1
13	The Additive Role of Angiogenic Markers for Women with Confirmed Preeclampsia. <b>2022</b> ,	0
12	Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia. 1-11	0
11	One-third of patients with eclampsia at term do not have an abnormal angiogenic profile. <b>2022</b> ,	0
10	New immune horizons in therapeutics and diagnostic approaches to preeclampsia	0
9	Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction. <b>2023</b> , 24, 972	2
8	Effect of Resveratrol on Pregnancy, Prenatal Complications and Pregnancy-Associated Structure Alterations. <b>2023</b> , 12, 341	0
7	Utility of sFtl-1 and Placental Growth Factor Ratio for Adequate Preeclampsia Management. <b>2023</b> , 11, 381	0
6	Proteomic profile of extracellular vesicles in maternal plasma of women with fetal death. <b>2023</b> , 36,	0
5	A bibliometric review of 35 years of studies about preeclampsia. 14,	0
4	Blood pressure patterns of hypertensive disorders of pregnancy in first and second trimester and contributing factors: a retrospective study. <b>2023</b> , 43,	0

- 3 Estrogen Actions in Placental Vascular Morphogenesis and Spiral Artery Remodeling: A Comparative View between Humans and Mice. **2023**, 12, 620 ○
- 2 To the question of the clinical predictive value of the sFlt-1:PlGF ratio is related to the placental dysfunction. **2023**, 21-29 ○
- 1 Short stature in small-for-gestational-age offspring born to mothers with hypertensive disorders of pregnancy. **2023**, 42, ○